Efficacy and Safety of Two Epidural Magnesium Sulfate Regimens for Post-Cesarean Analgesia: A Prospective, Randomized Controlled Trial
Bali Journal of Anesthesiology · 2026-07 · 10 (3) · 157-160
DOI: 10.4103/bjoa.bjoa_21_26 ↗Abstract
Abstract Background: Optimal post-cesarean analgesia is critical for recovery. Magnesium sulfate (MgSO 4 ) is a known neuraxial adjuvant acting as an N-methyl-D-aspartate antagonist, yet the ideal dose balancing efficacy and neonatal safety remains undefined. This trial evaluated two low-dose epidural magnesium regimens. Materials and Methods: A prospective, double-blind, randomized controlled trial was conducted with 340 American Society of Anesthesiologists I–II parturients undergoing elective cesarean section. Patients received lidocaine 2% (300 mg) plus fentanyl (100 µg), supplemented with either 75 mg (Group SM75) or 100 mg (Group SM100) of MgSO 4 . Primary outcomes included pain intensity (visual analog scale [VAS] scores) at 2, 4, 8, 12, and 24 h. Secondary outcomes assessed rescue analgesia, block regression, and neonatal well-being (Apgar/resuscitation needs). Results: The SM75 group showed significantly lower pain scores at 2, 12, and 24 h compared to SM100 ( P < 0.05). At 24 h, 47.1% of the SM75 group reported zero pain (VAS 0), a result not achieved in the SM100 group ( P = 0.003). While rescue analgesia was similar, the SM100 group had a higher incidence of transient neonatal depression, though 5-min Apgar scores were comparable. Conclusion: Epidural MgSO 4 at 75 mg provides superior sustained analgesia and a better neonatal safety profile compared to 100 mg of MgSO 4 . Lower neuraxial doses appear to optimize the therapeutic index in obstetric anesthesia.
EUVIMED